论文部分内容阅读
科技日报上海9月26日电(记者唐先武通讯员林峰)经过17年的不懈努力,国家肝癌科学中心主任、第二军医大学国际合作信号转导研究中心主任王红阳院士领衔的课题组,成功研发出具有自主知识产权的新型肝癌诊断试剂Glypican-3(简称GPC3)。近日,该课题组与福州迈新生物技术开发有限公司联合申报的GPC3检测试剂盒,获得国家食品药品监督管理总局颁发的三类医疗器械注册证,将正式临床推广应用。据王红阳介绍,此试剂盒主要用于肝癌的病理诊断
Shanghai Science and Technology Daily Shanghai, September 26 (Reporter Tang Xianwu correspondent Lin Feng) After 17 years of unremitting efforts, the National Liver Cancer Science Center, Second Military Medical University Center for International Cooperation Signal Transducers Wang Hongyang academician led the group successfully developed with Glypican-3 (GPC3), a new diagnostic reagent for liver cancer with independent intellectual property rights. Recently, the group and Fuzhou Mai new biotechnology Development Co., Ltd. joint declaration of the GPC3 detection kit, the State Food and Drug Administration issued three types of medical device registration card, will be formally clinical application. According to Wang Hongyang introduction, this kit is mainly used for pathological diagnosis of liver cancer